Company: PFSA
Filing Date: 2025-05-15
Form Type: 424B3
Source: 0001213900-25-044417
Chunk: 496

Company: Profusa, Inc.
Filing Date: 2025-05-15
Form: 424B3
Chunk 496
---
 on his healthcare focused experience. Corporate Governance We will structure our corporate governance in a manner NorthView and Profusa believe will closely align our interests with those of our stockholders following the Business Combination. Notable features of this corporate governance include: •we will have a majority of independent directors and independent director representation on our audit, compensation and nominating committees immediately following the consummation of the Business Combination, and our independent directors will meet regularly in executive sessions without the presence of our corporate officers or non -independentdirectors; •at least one of our directors will qualify as an “audit committee financial expert” as defined by the SEC; and •we will implement a range of other corporate governance practices, including implementing a robust director education program.

292 Classification of Board of Directors Following completion of the Business Combination, New Profusa’s board of directors will consist of five members and be divided into three classes of directors that will serve staggered three -yearterms. At each annual meeting of stockholders, a class of directors will be elected for a three -yearterm to succeed the same class whose term is then expiring. As a result, only one class of directors will be elected at each annual meeting of our stockholders, with the other classes continuing for the remainder of their respective three -yearterms. Our directors will be divided among the three classes as follows: •the Class I director will be Lauren Chung, and her terms will expire at the first annual meeting of stockholders to be held after the completion of the Business Combination; •the Class II directors will be Jack Stover and Peter O’Rourke, and their terms will expire at the second annual meeting of stockholders to be held after the completion of the Business Combination; and •the Class III directors will be Ben Hwang and Rajesh Asarpota, and their terms will expire at the third annual meeting of stockholders to be held after the completion of the Business Combination. The New Profusa Board intends for Dr. Hwang to serve as both Chairman of the Board and Chief Executive Officer of New Profusa following the completion of the Business Combination, and for Mr. O’Rourke to serve as the Lead Independent Director of New Profusa. The New Profusa Board believes that this strikes an appropriate balance between strong Company leadership with deep knowledge of New Profusa’s business through a combined Chairman of the Board and Chief Executive Officer role, and independent oversight through a Lead Independent Director position. More specifically, the New Profusa Board believes that the Lead Independent Director position helps maintain